Vor Biopharma Inc. filings document a clinical-stage biotechnology issuer focused on telitacicept and autoimmune disease development. The record includes Form 8-K disclosures for operating and financial results, Regulation FD presentations, clinical and regulatory updates, material agreements, governance changes and capital-structure matters.
Proxy materials describe director elections, equity incentive plan matters, auditor ratification and annual-meeting voting procedures. Other filings address executive compensation arrangements, Nasdaq-listed common stock, a reverse stock split, equity plan share adjustments and security-holder rights tied to the company’s common stock and outstanding awards.
VOR BIOPHARMA INC. reports an amended group Schedule 13G/A disclosing beneficial ownership positions held by several Venrock-related entities and named individuals as of March 31, 2026.
The filing states the Reporting Persons collectively hold positions capped at 5,083,877 shares each under a 9.99% beneficial ownership blocker tied to Pre-Funded Warrants. The company had 48,847,504 shares outstanding as of March 23, 2026 and 2,042,158 shares issuable on the Pre-Funded Warrants — figures used to calculate the reported 9.99% ownership percentages.
VOR Biopharma ownership filing: Verve Capital Limited reports beneficial ownership of 4,999,272 shares of common stock, representing 9.3% of the class as of March 31, 2026. The filing notes pre-funded warrants exercisable for 269,912 shares and bases its percentage on 48,847,504 shares outstanding as of March 23, 2026, adjusted for 4,729,360 shares issued upon exercise of pre-funded warrants on March 23, 2026.
Vor Biopharma reports first-quarter 2026 results showing it remains a clinical-stage company investing heavily in autoimmune programs while holding a large cash balance. The company recorded a net loss of $219.6 million for the three months ended March 31, 2026, largely driven by a $188.4 million non‑cash loss from the change in fair value of warrant liabilities.
Operating expenses were $35.2 million, with research and development at $17.6 million as spending shifted from legacy oncology programs to new telitacicept trials in generalized myasthenia gravis and Sjögren’s disease. General and administrative costs rose to $17.6 million, mainly from higher stock‑based compensation and commercial planning.
Vor reported cash, cash equivalents and marketable securities of $491.5 million as of March 31, 2026 and expects this to fund operations into early 2029. The company also highlighted multiple equity financings and warrant structures, including liability‑classified 2025 warrants with a fair value of $638.5 million, as key elements of its capital structure.
VOR BioPharma reports amended ownership disclosures by Qiming-related entities. The filing shows Qiming Venture Partners VIII-HC, L.P. beneficially owns 1,089,767 shares (2.0%), and Qiming Venture Partners VIII Investments, LLC beneficially owns 910,172 shares (1.7%). The filing cites 54,185,582 shares outstanding as of March 31, 2026 for percentage calculations.
The cover pages and incorporated items specify voting and dispositive power figures for each reporting person and include a joint filing agreement incorporated by reference.
VOR Biopharma Inc. amendment to a Schedule 13G/A reports that FMR LLC beneficially owns 1,539,670 shares of common stock, representing 3.2% of the class. The filing states FMR LLC has sole dispositive power over 1,539,670 shares and discloses related signature and exhibit references.
Vor Biopharma Inc. files a preliminary shelf prospectus to register for resale up to 5,338,078 shares of its common stock held by investors from a March 30, 2026 private placement. The shares were issued at $14.05 per share; Vor will receive no proceeds from resales. The registration satisfies contractual registration rights and the company agreed to use reasonable best efforts to have the registration declared effective.
Vor Biopharma Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 11, 2026 at 9:00 a.m. Eastern Time. Holders of common stock at the April 15, 2026 record date may vote online or by proxy.
Stockholders will elect two Class II directors, Fouad Namouni and Andrew Levin, for terms running to the 2029 meeting, consider an amendment and restatement of the 2021 Equity Incentive Plan, and ratify Ernst & Young LLP as independent auditor for 2026. The amended plan keeps a 4% annual “evergreen” share increase but bases it on both common shares outstanding and shares issuable upon exercise of pre-funded warrants, and adds full vesting on death for time-based awards held by employees unless an award agreement provides otherwise.
Vor Biopharma Inc. reported an open‑market sale of its common stock by entities associated with RA Capital. On April 22, 2026, RA Capital Healthcare Fund LP sold 165,150 shares of Vor Biopharma common stock at a weighted average price of $15.77, through multiple trades between $15.75 and $15.85. After these transactions, the fund continued to hold 2,402,095 shares indirectly reported. RA Capital Management, L.P., its general partner RA Capital Management GP, LLC, and managing members Dr. Peter Kolchinsky and Mr. Rajeev Shah each disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests.